Literature DB >> 16170134

Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia.

Q D Nguyen, S Shah, S Tatlipinar, D V Do, E V Anden, P A Campochiaro.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16170134      PMCID： PMC1772874     

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  2 in total

1.  Pegaptanib for neovascular age-related macular degeneration.

Authors:  Evangelos S Gragoudas; Anthony P Adamis; Emmett T Cunningham; Matthew Feinsod; David R Guyer
Journal:  N Engl J Med       Date:  2004-12-30       Impact factor: 91.245

2.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245
  2 in total
  43 in total

Review 1.  Vascular endothelial growth factor biology: clinical implications for ocular treatments.

Authors:  R B Bhisitkul
Journal:  Br J Ophthalmol       Date:  2006-12       Impact factor: 4.638

2.  Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration.

Authors:  Ratimir Lazic; Nikica Gabric
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-11-18       Impact factor: 3.117

3.  Effects of bevacizumab on retinal function in isolated vertebrate retina.

Authors:  M Lüke; M Warga; F Ziemssen; F Gelisken; S Grisanti; T Schneider; C Lüke; M Partsch; K U Bartz-Schmidt; P Szurman
Journal:  Br J Ophthalmol       Date:  2006-06-05       Impact factor: 4.638

4.  Which treatment is best for which AMD patient?

Authors:  P Kroll; C H Meyer
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

5.  Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues.

Authors:  P J Rosenfeld
Journal:  Br J Ophthalmol       Date:  2007-02       Impact factor: 4.638

6.  Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells.

Authors:  M S Spitzer; B Wallenfels-Thilo; A Sierra; E Yoeruek; S Peters; S Henke-Fahle; K U Bartz-Schmidt; P Szurman
Journal:  Br J Ophthalmol       Date:  2006-05-24       Impact factor: 4.638

7.  Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration.

Authors:  Quan Dong Nguyen; Syed Mahmood Shah; Gulnar Hafiz; Diana V Do; Julia A Haller; Roberto Pili; Ingrid E Zimmer-Galler; Kashif Janjua; R C Andrew Symons; Peter A Campochiaro
Journal:  Am J Ophthalmol       Date:  2007-12-11       Impact factor: 5.258

8.  Antipermeability and antiproliferative effects of standard and frozen bevacizumab on choroidal endothelial cells.

Authors:  Swaantje Peters; Sylvie Julien; Peter Heiduschka; Salvatore Grisanti; Focke Ziemssen; Martin Adler; Ulrich Schraermeyer; Karl-Ulrich Bartz-Schmidt
Journal:  Br J Ophthalmol       Date:  2006-12-19       Impact factor: 4.638

9.  An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization.

Authors:  Bing Xie; Jikui Shen; Aling Dong; Mara Swaim; Sean F Hackett; Lorenza Wyder; Susanne Worpenberg; Samuel Barbieri; Peter A Campochiaro
Journal:  FASEB J       Date:  2008-04-01       Impact factor: 5.191

10.  Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR).

Authors:  Stanislao Rizzo; Federica Genovesi-Ebert; Emanuele Di Bartolo; Andrea Vento; Sofia Miniaci; George Williams
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-02-20       Impact factor: 3.117
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.